Anemia aplásica asociada a hepatitis durante la pandemia por SARS-CoV-2

The hepatitis-associated aplastic anemia is one of the acquired bone marrow failure syndromes. It is a stereotyped form of presentation of aplastic anemia and accounts for 2 - 5 % of the cases in the West. Its treatment, which does not differ from that of aplastic anemia, consists of immunosuppressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Santarelli, Ignacio Martín, Manzella, Pedro Oscar, Gasco González, Francisco, Ingold, Julián José, Olivieri, Melissa Alejandra, Cloobs Venezia, Maximiliano Ariel, Fernández, Sofía Isabel, Melero, Marcelo José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Universidad Nacional de Córdoba 2022
Materias:
Casos Clínicos
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426336/
https://www.ncbi.nlm.nih.gov/pubmed/35700459
http://dx.doi.org/10.31053/1853.0605.v79.n2.35138
Descripción
Sumario:The hepatitis-associated aplastic anemia is one of the acquired bone marrow failure syndromes. It is a stereotyped form of presentation of aplastic anemia and accounts for 2 - 5 % of the cases in the West. Its treatment, which does not differ from that of aplastic anemia, consists of immunosuppression when bone marrow transplant is not possible. Nonetheless, during the SARS-CoV-2 pandemic, recommendations restricting the use of antithymocyte globulin to those cases with the highest risk of death have been issued, since the prognosis of CoViD-19 tends to be worse if administered. We present an otherwise-healthy 18-year-old male who was diagnosed with a hepatitis-associated aplastic anemia and received a personalized treatment following these recommendations.

Ejemplares similares